Dysregulation of brain and choroid plexus cell types in severe COVID-19
The annual societal cost of Parkinson's disease across Europe reached €22.8 billion in 2019 according to a new study within the EAN-led Cost of Illness in Neurology in Europe (COIN-Eu) initiative.
Latest Posts
-
-
Breaking newsCOVID-19Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial
Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial -
Breaking newsCOVID-19
Association Between SARS-CoV-2 Infection and Immune-Mediated Myopathy in Patients Who Have Died
Association Between SARS-CoV-2 Infection and Immune-Mediated Myopathy in Patients Who Have Died -
Breaking newsCOVID-19
Trends in Venous Thromboembolism Anticoagulation in Patients Hospitalized With COVID-19
Trends in Venous Thromboembolism Anticoagulation in Patients Hospitalized With COVID-19 -
Sperm Parameters Before and After COVID-19 mRNA Vaccination -
Breaking newsCOVID-19Depressive symptoms, mental wellbeing, and substance use among adolescents before and during the COVID-19 pandemic in Iceland: a longitudinal, population-based study
Depressive symptoms, mental wellbeing, and substance use among adolescents before and during the COVID-19 pandemic in Iceland: a longitudinal, population-based study -
Breaking newsCOVID-19Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial
Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial -
Breaking newsCOVID-19
Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial
Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial -
Breaking newsCOVID-19
Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial
Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial -
Tofacitinib in Patients Hospitalized with COVID-19 Pneumonia
-
Multisystem Inflammatory Syndrome in Children — Initial Therapy and Outcomes
-
Treatment of Multisystem Inflammatory Syndrome in Children
-
Interview with Prof. Ettore Beghi and Prof. Dániel Bereczki, co-chairs of the Neuroepidemiology Scientific Panel -
Paper of the MonthFeatured SliderResearch Paper of the month: Endovascular Therapy for Stroke Due to Basilar-Artery Occlusion
For July 2021, we have selected: Langezaal LCM et al. Endovascular Therapy for Stroke Due to Basilar-Artery Occlusion. N Engl J Med 2021; 384:1910-1920. DOI: 10.1056/NEJMoa2030297 -
InterviewsEAN NewsFeatured SliderProf. D. Muresanu and Prof. T. von Oertzen, Co-Chairs of the EAN Communication Committee interview Prof. J.M.K. Murthy, President of the Indian Academy of Neurology (IAN)
Interview with Prof. J.M.K. Murthy, President of the Indian Academy of Neurology (IAN)